Forcyte Biotechnologies focuses on innovating drug discovery in the field of mechanobiology to treat diseases such as asthma and fibrosis. The company employs patented bioMEMS technology to quantify cell strength, specifically their ability to pull or squeeze, which is crucial in understanding and treating mechanical diseases. By screening hundreds of thousands of drugs against various human cell types, Forcyte aims to map human mechanobiology comprehensively, thereby enabling the development of more effective therapies.
Forcyte Biotechnologies has made significant strides in building the world’s most comprehensive dataset in mechanobiology, linking genomics and pharmacology to mechanical cell function for the first time. This pioneering approach allows for the identification of better drugs more efficiently by focusing on cell function. The company's innovative technology and extensive research efforts position it as a leader in the field of functional biology, driving advancements in therapeutic development.
